T
TFF Pharmaceuticals
Early-stage biopharmaceutical company
About TFF Pharmaceuticals
TFF Pharmaceuticals specializes in developing advanced inhalation therapies using its proprietary Thin Film Freezing (TFF) technology. The company focuses on creating dry powder formulations for direct-to-lung delivery, which can improve the efficacy and safety of various medications. TFF Pharmaceuticals serves the pharmaceutical and biotechnology sectors, targeting conditions such as lung transplant rejection and fungal infections. The business model involves research and development, clinical trials, and partnerships with other pharmaceutical companies to bring its products to market. Revenue is generated through licensing agreements, milestone payments, and eventual product sales.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Austin, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Leidos
Series A1 investor entered at this stage
Liquid Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about TFF Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TFF Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.